We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Breakthrough Implant Marks Paradigm Shift in Treatment of Gastroesophageal Reflux

By HospiMedica International staff writers
Posted on 31 May 2023
Print article
Image: RefluxStop treats acid reflux without affecting the food passageway (Photo courtesy of Implantica AG)
Image: RefluxStop treats acid reflux without affecting the food passageway (Photo courtesy of Implantica AG)

Acid reflux, a condition characterized by the regurgitation of the stomach's acid content into the esophagus, affects approximately 400 million individuals daily, making it the second-largest treatment field globally. This condition can progress into a chronic disease known as gastroesophageal reflux disease (GERD) when acid reflux episodes become frequent. Traditional surgical treatments have been associated with numerous complications, such as difficulties in swallowing and an inability to belch or vomit. This is largely due to these methods encircling the food passage to bolster the closing ring muscle. Now, a novel implant based on a unique invention offers a solution to acid reflux without interfering with the food passageway.

Implantica AG’s (Zug, Switzerland) RefluxStop is a CE-marked implant designed to prevent gastroesophageal reflux and could potentially revolutionize the treatment of acid reflux. Unlike drug therapy, RefluxStop not only manages acid reflux symptoms but also eliminates stomach fluid regurgitation. This innovative, non-active implant is positioned on the upper section of the stomach through laparoscopic (keyhole) surgery.

The RefluxStop device obstructs the reflux process, which is triggered by anatomical misalignment associated with abnormal fundus contractions that also involve fluid, along with sphincter relaxation. Furthermore, it acts as a mechanical barrier that prevents the lower esophageal sphincter (LES) from shifting into the thorax. With abdominal pressure, the LES can function normally. RefluxStop was granted CE mark approval based on a multi-center clinical study demonstrating the device's safety and efficacy in patients. The study suggests that RefluxStop leads to lower complication rates compared to existing surgical treatments. Recently, RefluxStop won the Medtop Tech Award for the most innovative medical device among all competitors.

"We thank Medtop for acknowledging Implantica's premier commercial product, RefluxStop, as the most innovative medical device for 2023," said Dr. Peter Forsell, CEO and founder of Implantica. "This is validation that RefluxStop truly is a breakthrough in treating acid reflux. RefluxStop is making strides in demonstrating outstanding clinical results, enabling Reflux experts to offer a unique therapeutic solution to help millions of patients with acid reflux around the world."

Related Links:
Implantica AG

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Stereotactic Ultralight System
SUSy

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.